Clinical trial · Observational
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
Risk Factors for Dyspnea and Cardiotoxicity in Patients With Multiple Myeloma Who Receive Carfilzomib: A Prospective Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study terminated by PI
Summary
Brief summary (as posted)
This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the health of a patient's blood vessels. These assessments will help doctors leading the study determine the reasons why patients may develop shortness of breath (dyspnea) when being treated with carfilzomib and ways to better prevent this shortness of breath.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiotoxicity | — | UNRESOLVED | — |
| Dyspnea | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Shortness of Breath | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood Pressure Cuff | Device | — | UNRESOLVED |
| Blood Tests | Other | — | UNRESOLVED |
| Echocardiogram | Diagnostic Test | — | UNRESOLVED |
| EndoPAT | Device | — | UNRESOLVED |
| Quality of Life Assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Participants with Normal Baseline Endothelial Function
- interventionNames
- Device: EndoPAT
- Device: Blood Pressure Cuff
- Diagnostic Test: Echocardiogram
- Other: Quality of Life Assessment
- Other: Blood Tests
- label
- Participants with Abnormal Baseline Endothelial Function
- interventionNames
- Device: EndoPAT
- Device: Blood Pressure Cuff
- Diagnostic Test: Echocardiogram
- Other: Quality of Life Assessment
- Other: Blood Tests
Primary outcomes (1)
- measure
- Endothelial Function and Dyspnea Associations in Multiple Myeloma Patients
- timeFrame
- 2 months
- description
- The association between baseline endothelial function and dyspnea in myeloma patients treated with carfilzomib. These associations will be assessed by comparing endothelial function within two cohorts: patients with abnormal baseline endothelial function, and patients with normal baseline endothelial function. Baseline endothelial function will be measured using EndoPat, an FDA-approved device used for health tests. Dyspnea rates will be assessed by participant-reported outcomes using the FACIT Dyspnea-10 Raw Dyspnea Score and Common Terminology Criteria for Adverse Events V5.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 * Confirmed diagnosis of multiple myeloma * Newly-diagnosed multiple myeloma, or relapsed/refractory multiple myeloma with receipt of 1-3 previous lines of therapy and with a 2-week washout from prior therapy * Receiving carfilzomib as either standard-of-care therapy or as part of a clinical trial Exclusion Criteria: * Previous receipt of anthracycline chemotherapy * Previous receipt of carfilzomib * Four or more previous lines of therapy * Active pregnancy at the time of enrollment
References
Publications (0)
Data not yet available